Concurrent illness or major life stress occurring alongside GLP-1 therapy
Recent data from the Central Drugs Standard Control Organization notes that the approval process for new drugs can take between 12 to 24 months, leading to delays in product launches
Weight loss drugs have been available since the 1930s, but their popularity surged recently after the Food and Drug Administration (FDA) approved three GLP-1 receptor agonists for weight loss: Wegovy (semaglutide), Saxenda (liraglutide), and Ozempic (tirzepatide)
The glucagon receptor component does not appear to cause significant glucose-raising effects in the context of GLP-1 co-activation, suggesting that the three receptor pathways balance each other in important ways
While Semaglutide revolutionized the market, the addition of the GIP receptor in Tirzepatide showed that multi-pathway targeting was more effective
Fat loss in the face can lead to a gaunt appearance, increased skin laxity and deeper wrinkles